Free Trial

STERIS plc (NYSE:STE) Stock Position Lessened by Speece Thorson Capital Group Inc.

STERIS logo with Medical background

Speece Thorson Capital Group Inc. reduced its holdings in shares of STERIS plc (NYSE:STE - Free Report) by 11.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 69,391 shares of the medical equipment provider's stock after selling 8,914 shares during the period. STERIS comprises approximately 3.1% of Speece Thorson Capital Group Inc.'s portfolio, making the stock its 10th biggest holding. Speece Thorson Capital Group Inc. owned about 0.07% of STERIS worth $15,256,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of STE. UBS Group AG grew its position in STERIS by 17.1% during the third quarter. UBS Group AG now owns 143,822 shares of the medical equipment provider's stock valued at $31,557,000 after acquiring an additional 21,024 shares during the last quarter. Blair William & Co. IL grew its holdings in shares of STERIS by 3.0% in the third quarter. Blair William & Co. IL now owns 16,437 shares of the medical equipment provider's stock worth $3,607,000 after purchasing an additional 474 shares during the last quarter. Greenleaf Trust grew its holdings in shares of STERIS by 2.8% in the third quarter. Greenleaf Trust now owns 1,888 shares of the medical equipment provider's stock worth $414,000 after purchasing an additional 51 shares during the last quarter. Fiera Capital Corp bought a new position in shares of STERIS in the third quarter worth approximately $241,000. Finally, Catalyst Capital Advisors LLC bought a new position in shares of STERIS in the third quarter worth approximately $25,000. 94.69% of the stock is currently owned by institutional investors.


Insider Buying and Selling at STERIS

In other STERIS news, Director Jacqueline B. Kosecoff sold 4,584 shares of the firm's stock in a transaction on Monday, May 13th. The stock was sold at an average price of $231.53, for a total transaction of $1,061,333.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Jacqueline B. Kosecoff sold 4,584 shares of the firm's stock in a transaction on Monday, May 13th. The stock was sold at an average price of $231.53, for a total transaction of $1,061,333.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Renato Tamaro sold 1,154 shares of the firm's stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $231.64, for a total value of $267,312.56. Following the transaction, the vice president now owns 6,677 shares of the company's stock, valued at $1,546,660.28. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 7,762 shares of company stock valued at $1,798,477. 0.95% of the stock is currently owned by company insiders.

STERIS Trading Down 1.2 %

STE stock traded down $2.76 on Friday, reaching $218.29. The company's stock had a trading volume of 694,341 shares, compared to its average volume of 465,019. The business has a fifty day simple moving average of $217.61 and a two-hundred day simple moving average of $220.08. STERIS plc has a 12-month low of $195.47 and a 12-month high of $254.00. The firm has a market cap of $21.58 billion, a PE ratio of 57.14 and a beta of 0.85. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.36 and a current ratio of 3.08.

STERIS (NYSE:STE - Get Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The medical equipment provider reported $2.58 EPS for the quarter, beating the consensus estimate of $2.41 by $0.17. The business had revenue of $1.42 billion during the quarter, compared to analyst estimates of $1.41 billion. STERIS had a return on equity of 13.73% and a net margin of 6.95%. The company's revenue for the quarter was up 10.8% on a year-over-year basis. During the same quarter last year, the firm posted $2.30 earnings per share. As a group, research analysts forecast that STERIS plc will post 9.24 EPS for the current year.

STERIS Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 26th. Shareholders of record on Wednesday, June 12th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 0.95%. The ex-dividend date of this dividend is Wednesday, June 12th. STERIS's dividend payout ratio is currently 54.45%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Needham & Company LLC restated a "hold" rating on shares of STERIS in a report on Friday, May 10th. JMP Securities restated a "market outperform" rating and issued a $265.00 target price on shares of STERIS in a report on Thursday, May 9th. Piper Sandler restated a "neutral" rating and issued a $225.00 target price (up previously from $220.00) on shares of STERIS in a report on Friday, May 10th. Finally, StockNews.com raised STERIS from a "hold" rating to a "buy" rating in a research note on Saturday. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, STERIS has a consensus rating of "Moderate Buy" and a consensus target price of $241.60.

Read Our Latest Report on STERIS

About STERIS

(Free Report)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Featured Articles

Institutional Ownership by Quarter for STERIS (NYSE:STE)

Should you invest $1,000 in STERIS right now?

Before you consider STERIS, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.

While STERIS currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

CPI News Breakdown: Key Market Moves to Follow
Understanding Oversold Stocks
Inside Pelosi’s Latest Stock Moves

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines